|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. Paul R. Perreault B.A.||MD, CEO & Exec. Director||4,23M||N/A||1957|
|Mr. David Mark Lamont C.A., ACA, BCom||Chief Financial Officer||1,84M||N/A||1966|
|Dr. Paul F. McKenzie||Chief Operating Officer||2,74M||N/A||1966|
|Dr. Robert Andrew Cuthbertson A.O., BMedSci, MBBS, Ph.D., FTSE, FAHMS, AO||Sr. Adviser & Exec. Director||1,48M||N/A||1955|
|Ms. Joy Carolyn Linton BComm, Grad Dip AFI, GAICD||Chief Financial Officer||N/A||N/A||1965|
|Mr. Mark Dehring||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Gregory Boss B.S., BS(Hons), J.D.||Exec. VP of Legal & Group Gen. Counsel||N/A||N/A||1961|
|Christina Hickie||Sr. Mang. of Communications||N/A||N/A||N/A|
|Ms. Elizabeth Walker B.A., M.S.||Exec. VP & Chief HR Officer||N/A||N/A||1970|
|Dr. Karen Etchberger||Exec. VP of Quality & Bus. Services||N/A||N/A||1958|
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
El ISS Governance QualityScore de CSL Limited, a día 6 de octubre de 2020, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 3; Derechos de los accionistas: 1; Compensación: 1.